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There are limited data evaluating the relationship between influenza treatment and
hospitalization duration. Our purpose assessed the association between different
treatments and hospital stay among Korean pediatric influenza patients. Total 770 children
≤ 15 yr-of-age hospitalized with community-acquired laboratory-confirmed influenza at
three large urban tertiary care hospitals were identified through a retrospective medical
chart review. Demographic, clinical, and cost data were extracted and a multivariable
linear regression model was used to assess the associations between influenza treatment
types and hospital stay. Overall, there were 81% of the patients hospitalized with
laboratory-confirmed influenza who received antibiotic monotherapy whereas only 4% of
the patients received oseltamivir monotherapy. The mean treatment-related charges for
hospitalizations treated with antibiotics, alone or with oseltamivir, were significantly
higher than those treated with oseltamivir-only (P < 0.001). Influenza patients treated
with antibiotics-only and antibiotics/oseltamivir combination therapy showed 44.9% and
28.2%, respectively, longer duration of hospitalization compared to those treated with
oseltamivir-only. Patients treated with antibiotics, alone or combined with oseltamivir,
were associated with longer hospitalization and significantly higher medical charges,
compared to patients treated with oseltamivir alone. In Korea, there is a need for more
judicious use of antibiotics, appropriate use of influenza rapid testing.
Keywords: Influenza, Human; Hospitalizations; Oseltamivir; Therapeutics; Child
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INTRODUCTION
Influenza viruses are common respiratory pathogens among
all age groups and are major causes of excess respiratory disease-associated hospitalizations, mortality, and costs during
annual epidemics and pandemics (1, 2). Children with underlying medical conditions and younger age, especially ≤ 5 yr
olds, are at high risk for severe influenza-associated outcomes
(3-5). Furthermore, pediatric influenza exerts a considerable
socioeconomic burden in terms of direct and indirect costs,
and excess health-care utilization (6-8). Children also serve as a
reservoir for household transmission of influenza, causing secondary illness in the family (8, 9).
Currently available neuraminidase inhibitors are effective in
reducing influenza-associated illness duration, severity, com-

plication risks, influenza-related mortality and even antibiotic
use (10-12). Often patients hospitalized with influenza-related
illnesses are inappropriately treated with antibiotics as prophylactic and empiric therapy, as indicated by increased antibiotic
prescriptions during the influenza season (10, 13). The emergence of drug resistance and over-prescription of antibiotics are
growing public health issues, as well as increased healthcare
costs without reductions in illness duration (14-16).
Republic of Korea (ROK) has a relatively high influenza vaccination coverage rate of nearly 40% in the general population
(17) and this is higher than the vaccination rate among children
hospitalized with acute respiratory infection in the US (18) and
similar to that of healthy Ontario children in Canada (19). None
theless, Korea still suffers from considerable disease burden of
influenza in children, where 20% of viral respiratory disease hos
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pitalizations are due to influenza virus infection (20). This study
is the first to address treatment patterns in influenza-associated
hospitalizations among Korean children. To address existing
gaps in knowledge regarding childhood influenza in Korea, we
evaluated the association between hospitalization duration and
treatment type, using clinical and epidemiological data from
children hospitalized with laboratory-confirmed influenza. We
also described the economic burden by calculating medical
charges incurred during hospitalization by treatment type.

MATERIALS AND METHODS
Study hospital and cohort
A retrospective review of medical records for patients admitted
or treated from February 2004 through June 2007 was conducted at three academic, tertiary-care hospitals. Ansan, Anam, and
Guro Hospitals, affiliated with Korea University (KU), serve the
communities of Ansan city (a neighboring city of Seoul), and
districts of Anam and Guro in Seoul, respectively. At these KU
hospitals, nasal aspirate specimens were systematically collected from patients presenting with acute respiratory symptoms
and routinely tested to identify adenovirus, parainfluenza, respiratory syncytial virus (RSV) and influenza A/B with virus.
Additionally, selected patients were tested for influenza A/B
and RSV by rapid antigen detection (Directigen EZ Flu A+B Test
Kit, Becton-Dickinson, NJ, USA) at the clinicians’ discretion.
For this study, we included patients who: a) presented with
respiratory symptoms at one of the KU hospitals, b) were ≤ 15
yr-of-age at the time of admission, and c) had laboratory-confirmation of influenza A/B. Children with mixed viral infections
(with following viruses; influenza, RSV, parainfluenza, or ade-

novirus) and with recurrent episodes with the same virus type
who returned to the hospital within two weeks from the date of
the previous discharge or clinic visit were excluded from our
analysis. Assembly of the study patient cohort is outlined in Fig.
1. During the 41 months, 1,039 episodes of laboratory-confirm
ed influenza were identified from the outpatient and inpatient
departments of the three hospitals.
Virus detection
Viral culture had been performed using an enhanced cell culture method with fluorescent antibody detection. Specimens
(200 μL) were inoculated onto R-Mix Ready Cells (Diagnostic
Hybrids, NY, USA), and vials were centrifuged at 700 × g for 60
min at room temperature. After overnight incubation at 35°C in
a CO2 incubator, cell monolayers were washed with phosphatebuffered saline, fixed with acetone, and stained with a respiratory virus fluorescent antibody pool, D3 DFA (Diagnostic Hybrids). When virus specific fluorescence was noted, virus identification was performed by using individual monoclonal antibodies (Diagnostic Hybrids). The presence of three or more cells
per well with specific apple-green fluorescence was considered
positive identification. Screenings were done on day 1 and 3.
Additionally, selected patients were tested for influenza A/B
and RSV by rapid antigen detection (Directigen EZ Flu A+B Test
Kit, Becton-Dickinson) at the clinicians’ discretion.
Data collection
Via medical chart reviews of 1,039 episodes of community-acquired laboratory-confirmed influenza, we extracted the following demographic and clinical variables from the KU hospital electronic medical information database: influenza virus

Episodes tested for influenza virus among patients ≤15 yr with respiratory symptoms during the study period
(n = 2,781)
Lab-confirmed influenza infection episodes
(n = 1,039)
Outpatients
(n = 205)

Inpatients
(n = 825)

Nosocomial infections
(n = 19)

Basic supportive case
(n = 56)

Non-influenza episodes
(n = 1,742)

Antibiotic treatment
(n = 687)

Recurrent cases
(n = 9)

Community-acquired infection
(n = 806)

Oseltamivir given within 2 days
(n = 94)

Oseltamivir given after 2 days
(n = 23)

Amantadine treatment
(n = 13)

Analysis cohort
(n = 770)
Fig. 1. Flow chart describing the ascertainment of the patient cohort with hospitalization identified during the study period of February 2004-June 2007.
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type, dates of admission and discharge, diagnoses, signs and
symptoms, body temperature, duration of fever, pre-existing
medical conditions, vital signs, hematologic and radiologic test
results, treatment information, and discharge status. Direct hospital medical charges were obtained from the hospital billing/
registry office. Treatment-related fee was composed of charges
for injection, medication, treatment material, physical therapy,
surgery, anesthesia, and blood infusion. Testing fee consisted of
charges for routine and specially-ordered laboratory and diagnostic tests. Hospital admission fee included admission, food,
and room charges. They were summed for the total hospital
charges incurred and currency was converted from Korean Won
(KRW) to US dollar with the average exchange rate during study
period of 1 KRW = 0.0007 US$.
The diagnosis at admission was categorized by the primary
clinical manifestation. Diagnoses of pneumonia, bronchitis,
croup, and asthma were grouped as lower respiratory tract illness (LRTI), while acute pharyngitis, sinusitis, and laryngitis
were grouped as upper respiratory illness (URI). Urinary tract
infection, sepsis, and neurologic (e.g., convulsions, febrile seizure, Guillain-Barré Syndrome), gastrointestinal (e.g., diarrhea,
acute gastroenteritis), and cardiovascular conditions were group
ed as ‘non-respiratory’ diseases. An axillary (tympanic membrane) temperature ≥ 37.5 (37.8)°C was defined as fever. Fever
duration included the febrile days prior to admission.
Variable construction and statistical analysis
The analysis examined the relationship between the length of
hospital stay (LOS) and the different types of treatment administered during hospitalization, when adjusted for potential confounding factors. Nosocomial influenza episodes with virus detection ≥ 7 days after the date of admission were excluded from
the analysis sample. In accordance with current guidelines of
influenza treatment, episodes treated with oseltamivir (Tamiflu®, Roche Pharmaceuticals, Basel, Switzerland) outside of the
recommended two-day window after the onset of symptoms,
and episodes treated with amantadine were excluded.
The mean peak body temperature for study patients measured during hospitalization, 38.6°C, was used as the cutoff value to create a dichotomous variable indicating elevated body
temperature. Normal white blood cell (WBC) count was defin
ed as WBC of 5,000-19,500/µL for children ≤ 10 months-of-age;
6,000-17,500/µL for those 11 months-2 yr-of-age; 5,500-15,500/
µL for children 3-7 yr-of-age; and 4,500-13,500 (11,500)/µL for
children 8-13 (14-15) yr-of-age (21). Leukopenia and leukocytosis were below the lower and above the upper values of the
normal WBC range, respectively. Complications that occurred
during hospitalization were categorized into secondary bacterial pneumonia, other secondary bacterial infection, encephalitis, or exacerbation of the pre-existing medical conditions. Preexisting medical conditions were congenital diseases and achttp://dx.doi.org/10.3346/jkms.2014.29.4.485

quired diseases (e.g., asthma, and cancer). Binary variables were
created for the presence or absence of complications and preexisting conditions.
Influenza hospitalizations with complete data were divided
into four treatment categories: oseltamivir-only, antibiotics-only, antibiotics-plus-oseltamivir, and supportive-care without
antiviral or antibiotic treatment. Categorical pair-wise comparisons were made with reference to the oseltamivir-only group
using chi-square or the Fisher’s exact tests with significance at
P < 0.05. Comparison of continuous variables was performed
using the Student’s t-test. However, for hospital charges with
skewed distributions, the Mann-Whitney test was used to make
pair-wise comparisons with reference to the oseltamivir-only
group. Bivariate analyses were performed to identify potential
confounders and covariates of interest for the regression model,
using SAS® version 9.0 (SAS Institute, Cary, NC, USA).
To adjust for variability in initial severity of illness, clinical
parameters such as temperature measured at admission, presenting signs and symptoms (i.e., expectoration, diarrhea, headache, injected tympanic membrane, sore throat, vomiting, brea
thing difficulty, rales or wheezing), admission diagnosis, laboratory test results (i.e. WBC/neutrophil counts and chest infiltrates) were compared across treatment groups. Construction
of the model with these variables allows statistical adjustment
for initial variability in clinical presentation. As potential confounders, presence of underlying medical conditions and occurrence of complications during hospitalization, were included as dichotomous variables in the model to control for variations in disease presentation at admission and during clinical
course that may have guided treatment-related decisions. Some
variables that are closely related were assessed for multicolline
arity and were limited for inclusion in the regression model.
Multivariable linear regression was performed with the outcome as the log-transformed, hospitalization duration and categorical variable of influenza treatments as the main predictor.
The β, % change in treatment-related charges, and 95% confidence intervals (CI) were reported.
Ethics statement
Study approvals were obtained from the institutional review
boards of the KU Ansan Hospital (IRB No. ED0744 ) and the International Vaccine Institute (IRB No. 2007-008). The exemption of informed consent and assent forms was allowed by both
IRBs because this study was based on a retrospective review
and the patient IDs were removed from the DB provided by the
hospital records office.

RESULTS
Patient characteristics
Of the 770 hospitalizations in our analysis sample, 77% were ≤
http://jkms.org  487
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Hospitalization-associated medical charges
The mean treatment-related charges (US$171 and $111 vs $67,
P < 0.001 and < 0.001, respectively) and the hospital admission
charges (US$287 and $240 vs $176, P < 0.001 and 0.017, respectively) were significantly higher in the groups treated with antibiotics-only and antibiotics-plus-oseltamivir, compared to the
group treated with oseltamivir-only (Table 3). The mean total
charges for hospitalizations treated with antibiotics-only and
antibiotics-plus-oseltamivir were significantly higher than charges for hospitalizations treated with oseltamivir-only (US$753 and
$623 vs $508, P < 0.001 and 0.059, respectively).

5 yr-of-age (590/770) and there were twice more influenza A
positive episodes than influenza B episodes (62% vs 34%), with
few influenza A and B co-infections (Table 1). The distributions
of hospitalizations by age and gender in the oseltamivir-only
group were similar to those in other treatment groups. The distributions of influenza hospitalizations by virus type and admission diagnosis category were significantly different when
treatment groups were compared to the oseltamivir-only group.
The patients in the antibiotics-only, antibiotics-plus-oseltamivir, and supportive-care groups were more likely to be diagnos
ed at admission with LRTI than the oseltamivir-only group (57%,
42%, and 54% vs 19%, respectively).

Predictors of increased hospital stay
Compared with the oseltamivir-only group, children treated
with antibiotics-only showed 44.9% longer hospitalization compared to those who received oseltamivir-only (95% CI, 15.8581.33; P value = 0.001) (Table 4) in multivariate analysis. Treatment with antibiotics-plus-oseltamivir also showed a significantly longer LOS, compared to the oseltamivir-only group, by

Clinical characteristics
Among the total of 770 patients, 27 were treated with oseltamivir-only, 620 were treated with antibiotics-only, 67 received antibiotics-plus-oseltamivir and 56 patients received supportivecare. The mean LOS for patients in the antibiotics-only and antibiotics-plus-oseltamivir groups were significantly longer compared to the oseltamivir-only group (5.0 and 4.0 vs 3.0 days, respectively) (Fig. 2). The mean fever duration was significantly
longer in the antibiotics-only group compared to the oseltamivir-only group (5.5 vs 3.8 days). Patients in the oseltamivir-only
group were more likely to have received influenza rapid diagnostic tests (IRDT) than the antibiotics-only, antibiotics-plusoseltamivir, and supportive-care groups (82% vs 3%, 55%, and
16%, respectively) (Table 2). Patients who presented with rales/
wheezing were found more commonly in those three treatment
groups than in the oseltamivir-only group (38%, 37%, and 41%
vs 7%). Patients presenting with pharyngeal injection were significantly less common in the antibiotics-only group, compared
to the oseltamivir-only group (73% vs 93%). Overall, 12% of patients (n = 96/770) suffered from complications during hospitalization, and 45% (n = 43/96) developed secondary bacterial
pneumonia or other bacterial infection with few cases of neurologic problems (e.g. encephalitis) and exacerbation of pre-existing medical conditions (data not shown).

6
5

Duration (days)

Hospitalization
Fever

†

*
‡

4
3
2
1
0

Oseltamivir only
(reference)

Antibiotics
only

Antibiotics plus
oseltamivir

Supportive
care

Treatments
Fig. 2. Mean length of hospital stay and duration of fever in days for 770 hospitalizations with laboratory-confirmed influenza by the treatment type, February 2004-June
2007. *P < 0.001, for comparison of the mean duration of hospital stay in antibiotics-only (5.0 days the oseltamivir-only treatment groups (3.0 days); †P < 0.001, for
comparison of the mean fever duration in antibiotics-only (5.5 days) vs the oseltamivir-only treatment groups (3.8 days); ‡P = 0.012, for comparison of the mean duration of hospital stay in antibiotics-plus-oseltamivir (4.0 days the oseltamivir-only treatment groups (3.0 days).

Table 1. Characteristics of the analysis cohort of hospitalizations with laboratory-confirmed influenza identified during February 2004-June 2007 in Republic of Korea
Treatment group

No.

Mean age,
(yr ± SD)

Female

Oseltamivir-only (reference)
Antibiotics-only
Antibiotics-plus-oseltamivir
Supportive-care
Total

27
620
67
56
770

3.58 ± 3.91
3.39 ± 2.76
3.51 ± 2.90
3.77 ± 3.36
3.43 ± 2.86

12 (44.4)
264 (42.6)
27 (40.3)
17 (30.4)
320 (41.6)

Influenza virus type

Admission diagnosis

A

B

LRTI

URI

Non-respiratory

13 (48.2)
386 (62.3)*
43 (64.2)†
36 (64.3)‡
478 (62.1)

4 (14.8)
225 (36.3)
15 (22.4)
20 (35.7)
264 (34.3)

5 (18.5)
354 (57.1)§
28 (41.8)ll
30 (53.6)¶
417 (54.2)

12 (44.4)
184 (29.7)
29 (43.3)
15 (26.8)
240 (31.2)

10 (37.0)
82 (13.2)
10 (14.9)
11 (19.6)
113 (14.7)

Values are No. (%) unless otherwise noted. *P < 0.001, for comparison between the antibiotics-only vs oseltamivir-only treatment groups; †P = 0.050, for comparison between
the antibiotics-plus-oseltamivir vs oseltamivir-only treatment groups; ‡P < 0.001, for comparison between the supportive-care vs oseltamivir-only treatment groups; §P < 0.001,
for comparison between the antibiotics-only vs oseltamivir-only treatment groups; llP = 0.025, for comparison between the antibiotics-plus-oseltamivir vs oseltamivir-only treatment groups; ¶P = 0.010, for comparison between the supportive-care vs oseltamivir-only treatment groups. LRTI, lower respiratory tract illness; URI, upper respiratory illness.
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Table 2. Clinical characteristics of the 770 hospitalizations with laboratory-confirmed influenza treated with antiviral or antibiotic medication from February 2004 to June 2007
Treatment

Characteristics

Oseltamivir-only (reference)

Antibiotics-only

Antibiotics plus oseltamivir

Supportive-care

37.65 (0.85)
38.50 (0.69)
22 (81.5)

37.54 (0.98)
38.61 (0.86)
21 (3.4)*

37.79 (0.89)
38.87 (0.89)
37 (55.2)†

37.25 (0.80)
38.13 (0.99)
9 (16.1)‡

25 (92.6)
2 (7.4)
3 (11.1)

450 (72.7)§
237 (38.2)ll
60 (9.7)

52 (77.6)
25 (37.3)¶
7 (9.5)

43 (76.8)
23 (41.1)**
4 (5.4)

22 (81.5)
15 (55.6)
14 (51.9)
5 (18.5)
1 (3.7)
0
12 (44.4)
1 (3.7)

539 (86.9)
322 (51.9)
357 (57.6)
60 (9.7)
26 (4.2)
49 (7.9)
143 (23.1)§§
32 (5.2)

59 (88.1)
39 (58.2)
34 (50.8)
1 (1.5)††
3 (4.5)
3 (4.5)
16 (23.9)ll ll
2 (3.0)

50 (89.3)
38 (67.9)
28 (50.0)
8 (14.3)
3 (5.4)
16 (28.6)‡‡
10 (17.9)¶¶
11 (19.6)

5 (18.5)
20 (74.1)
2 (7.4)

123 (19.8)
465 (75.0)
32 (5.2)

13 (19.4)
52 (77.6)
2 (3.0)

18 (32.1)
36 (64.3)
2 (3.6)

26 (96.3)
5 (18.5)
3 (11.1)
1 (3.7)

541 (87.3)
194 (31.3)
80 (12.9)
53 (8.6)

59 (88.1)
10 (14.9)
4 (6.0)
5 (7.5)

49 (87.5)
17 (30.4)
9 (16.1)
7 (12.5)

Temperature at admission (°C) mean (SD)
Peak temperature during hospitalization (°C) mean (SD)
Received influenza rapid antigen detection test
Signs
Pharyngeal injection
Rales or wheezing
Injected tympanic membrane
Symptoms
Cough
Rhinorrhea
Expectoration
Diarrhea
Headache
Sore throat
Vomiting
Breathing difficulty
White blood cell count
Leukopenia
Normal
Leukocytosis
Neutrophil (ref. normal, 54%-62%)
Outside normal range
Chest radiograph infiltrates
Presence of complications
Presence of underlying diseases

Values are No. (%) unless otherwise noted. The 95% confidence intervals (95% CI) were reported. *P < 0.001, for comparison between the antibiotics-only vs oseltamivir-only
treatment groups; †P = 0.017, for comparison between the antibiotics-plus-oseltamivir vs oseltamivir-only treatment groups; ‡P < 0.001, for comparison between the supportivecare vs oseltamivir-only treatment groups; §P = 0.022, for comparison between the antibiotics-only vs oseltamivir-only treatment groups; llP = 0.001, for comparison between
the antibiotics-only vs oseltamivir-only treatment groups; ¶P = 0.004, for comparison between the antibiotics-plus-oseltamivir vs oseltamivir-only treatment groups; **P = 0.002,
for comparison between the supportive-care vs oseltamivir-only treatment groups; ††P = 0.002, for comparison between the antibiotics-plus-oseltamivir vs oseltamivir-only treatment groups; ‡‡P = 0.002, for comparison between the supportive-care vs oseltamivir-only treatment groups; §§P = 0.011, for comparison between the antibiotics-only vs oseltamivir-only treatment groups; ll llP = 0.049, for comparison between the antibiotics-plus-oseltamivir vs oseltamivir-only treatment groups; ¶¶P = 0.010, for comparison between
the supportive-care vs oseltamivir-only treatment group.

Table 3. Hospital charges (mean, SD) of patients with laboratory-confirmed influenza by treatment type, February 2004-June 2007
Type of hospital charge
Treatment-related
Hospital admission
Testing
Total

Treatment type
Oseltamivir-only (reference)
66.55 (37.39)
175.76 (92.45)
230.35 (156.88)
507.82 (208.36)

Antibiotics-only
170.67 (713.34)*
287.16 (335.04)‡
238.76 (193.89)
753.47 (1247.68)ll

Antibiotics plus oseltamivir
†

110.98 (60.28)
240.23 (158.49)§
226.88 (138.77)
623.18 (283.89)

Supportive-care
78.41 (77.69)
212.60 (112.64)
227.25 (167.84)
556.58 (248.91)

Mean values and standard deviation (in parenthesis) are reported in US$ with exchange rate of 1 KRW = 0.0007 US$. *P < 0.001, for comparison of the mean treatment-related fees in antibiotics-only vs the oseltamivir-only treatment groups; †P < 0.001, for comparison of the mean treatment-related fees in antibiotics-plus-oseltamivir vs the oseltamivir-only treatment groups; ‡P < 0.001, for comparison of the mean hospital admission charges in antibiotics-only vs the oseltamivir-only treatment groups; §P = 0.017,
for comparison of the mean hospital admission charges in antibiotics-plus-oseltamivir vs the oseltamivir-only treatment groups; llP < 0.001, for comparison of total hospital char
ges in antibiotics-only vs the oseltamivir-only treatment groups.

28.2% (95% CI, 1.96-61.11; P value = 0.034). From the univariate
analysis, patients who received the antibiotics-only therapy show
ed 55.8% longer hospitalization compared to those who received
oseltamivir-only (95% CI, 27.99-89.66; P value < 0.001) (data not
shown). Patients who received antibiotics-plus-oseltamivir therapy also showed a significantly longer LOS by 28.5%, compared
to the oseltamivir-only group (95% CI, 2.24-61.48; P value = 0.032).
Children in the 3-5 yr-old groups showed to have 12.6% shor
ter LOS, compared to infants ≤ 1 yr old (95% CI, -21.9~-2.18; P
http://dx.doi.org/10.3346/jkms.2014.29.4.485

value = 0.019). Patients with dyspnea had 18.0% longer LOS
compared to those without dyspnea (95% CI, 0.28-38.86; P value = 0.046), while those children with admission diagnosis categorized as URI showed 9.3% shorter LOS compared to those
with LRTI (95% CI, -17.52~-0.29; P value = 0.044). Also, the presence of chest radiograph infiltrates and pre-existing medical
conditions were significant indicators of lengthened hospitalization by 12.9% and 21.3%, respectively (95% CI, 3.50-23.04 and
6.27-38.32, respectively).
http://jkms.org  489
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Table 4. Multivariate regression analysis of association between treatment type received and hospitalization duration among 770 hospitalizations with laboratory-confirmed influenza in Republic of Korea, February 2004 through June 2007
Characteristics
Treatment received (ref. Oseltamivir-only)
Antibiotics-only
Antibiotics-plus-oseltamivir
Supportive-care
Age-group (yr) (ref. ≤ 1 yr)
2
3-5
6-15
Antigen detection test performed (ref. no)
Yes
Clinical attributes at admission
Body temperature (ref. < 38.6°C)
≥ 38.6°C
Unavailable
Presence of signs and symptoms (ref. absent)
Rales or wheezing
Expectoration
Diarrhea
Headache
Injected tympanic membrane
Sore throat
Vomiting
Breathing difficulty
Diagnosis (ref. LRTI)
URI
Non-respiratory
White blood cell count (ref. normal count)
Leucopenia
Leukocytosis
Neutrophil (ref. normal, 54%-62%)
Neutropenia
Neutrocytosis
Chest radiograph infiltrates (ref. absence)
Presence of pre-existing conditions (ref. absence)
Presence of complications (ref. absence)

B* (% change in hospitalization duration)

95% Confidence Interval (% change)

P value

0.372 (44.94)
0.248 (28.16)
0.100 (10.55)

0.147-0.595 (15.85-81.33)
0.019-0.477 (1.96-61.11)
-0.153-0.354 (-14.20-42.44)

0.001
0.034
0.437

-0.067 (-6.44)
-0.135 (-12.59)
-0.103 (-9.76)

-0.190-0.057 (-17.34- 5.88)
-0.247~-0.022 (-21.90~-2.18)
-0.233-0.028 (-20.77-2.79)

0.291
0.019
0.122

-0.044 (-4.33)

-0.196-0.107 (-17.79-11.32)

0.566

0.081 (8.40)
0.008 (0.77)

-0.034-0.195 (-3.30-21.52)
-0.084-0.100 (-8.10-10.49)

0.166
0.871

0.078 (8.15)
-0.015 (-1.44)
0.069 (7.15)
-0.068 (-6.57)
0.014 (1.41)
0.059 (6.04)
0.026 (2.59)
0.166 (18.00)

-0.011-1.168 (-1.09-18.26)
-0.091-0.062 (-8.67-6.35)
-0.059-0.197 (-5.75-21.83)
-0.252-0.116 (-22.30-12.33)
-0.111-0.139 (-10.48-14.88)
-0.074~-0.191 (-7.12~-21.07)
-0.063-0.114 (-6.10-12.07)
0.003-0.328 (0.280-38.86)

0.085
0.708
0.291
0.469
0.826
0.385
0.571
0.046

-0.098 (-9.31)
0.050 (5.18)

-0.193~-0.003 (-17.52~-0.29)
-0.077-0.177 (-7.37-19.42)

0.044
0.436

-0.080 (-7.65)
0.031 (3.12)

-0.173-0.014 (-15.91-1.42)
-0.140-0.201 (-13.03-22.27)

0.096
0.723

0.055 (5.64)
0.027 (2.69)
0.121 (12.85)
0.193 (21.24)
-0.026 (-2.57)

-0.061-0.171 (-5.90-18.60)
-0.089-0.142 (-8.53-15.28)
0.034-0.207 (3.50-23.04)
0.061-0.324 (6.27-38.32)
-0.141-0.089 (-13.13-9.27)

0.352
0.653
0.006
0.004
0.656

Note. ref denotes reference for each categorical variable. *In addition to the variables listed in the table, the multivariate analysis was adjusted for sex, influenza season, presence of signs/symptoms (chills, rales/wheezing, cough, expectoration, rhinorrhea, diarrhea, sore throat, pharyngeal injection, rhonchi, and headache).

DISCUSSION
This is the fir st study to compare influenza treatments in relation to hospitalization-associated outcomes among Korean
children. Our findings suggest that antibiotic therapy, alone or
in combination with oselatmivir, is associated with longer hospitalization, compared to oseltamivir monotherapy, among
children with laboratory-confirmed influenza. Also, our data
showed that the lowest mean total hospital charges, as well as
hospital admission and treatment-related charges, occurred
among patients treated with oseltamivir-only among different
influenza treatment options. In our sample of influenza hospitalizations, 81% of patients received antibiotic-only while only
4% received oseltamivir-only. Patients who received oseltamivir
monotherapy were more likely to be laboratory-confirmed with
IRDT in addition to culture tests than patients who received
other treatments.
Our results are consistent with findings from Kaiser et al. and
Gums et al. that demonstrated the effectiveness of oseltamivir
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in reducing the length of hospitalization (10, 22); and Sato, et al.
that showed a significantly shorter duration of fever in oseltamivir-treated influenza A patients (12). Our data showed a significantly longer mean LOS for patients in the antibiotics-only
and antibiotics-plus-oseltamivir groups compared to the oseltamivir-only group. Less timely onset of antibiotic therapy could
play a role in increased LOS, however, 99% (n = 683) of 687 antibiotics-treated patients received antibiotics within 3 days of
admission in our data, indicating the timing of antibiotic therapy was unlikely the cause of observed association. In the antibiotics-plus-oseltamivir group, 59 patients out of 67 had received
antibiotics before oseltamivir in our data. While this may be explained by the fact that these patients may have had clinical indications of bacterial pneumonia or other secondary infections,
this antibiotic prescription preceding oseltamivir treatment
could have led to delayed onset of oseltamivir therapy and consequently lengthening the patients’ LOS.
Several factors, indicating severe clinical course (e.g., complication) and initial differences in clinical presentation of illness,
http://dx.doi.org/10.3346/jkms.2014.29.4.485
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could have potentially influenced treatment-related decisions
and were taken into account in our multivariate modeling. It is
possible that additional confounding variables that were not
measured in this study may explain the relationship. However,
the observed strength of the relationship of oseltamivir-only
compared to antibiotics-only and antibiotics-plus-oseltamivir
groups (i.e., 45% and 28% increases in LOS with the P value of
0.001 and 0.034, respectively) makes it unlikely that our findings are a result of residual confounding not controlled for in
our models. While these findings are consistent with several reports of reduced hospitalization associated with oseltamivir
treatment (10, 22), no previous studies have shown that antibiotic treatments, compared to oseltamivir therapy, is associated
with longer LOS in children with laboratory-confirmed influenza.
Our finding that hospital charges were lowest among oseltamivir-only treated children also corresponds with previous stu
dies reporting that unnecessary costs may incur among influenza-like illness (ILI) patients treated with antibiotics (13, 16,
23) while oseltamivir is the cost-effective choice of influenza
treatment (24). The cost of influenza-related hospitalization in
our data was shown to be lower than previously estimated in
other countries (6, 7, 25). This is explained by the fact that ROK
has universal population coverage by the National Health Insurance that subsidizes physician fees, hospital and prescription drugs charges via a compulsory healthcare plan (26). Despite the number of studies that have previously reported an indiscriminant and inappropriate use of antibiotics (16, 27, 28),
antibiotics were demonstrated to still be a primary treatment
option for children hospitalized with influenza in ROK. Observ
ed treatment patterns may be explained, in part, by the absence
of standardized treatment guidelines for seasonal influenza in
ROK.
In addition to the absence of the treatment guidelines, infrequent use of the IRDT during the study period could lead to observed treatment patterns. Without test for viral pathogen, the
uncertainty of diagnosis of children with influenza-like illness
frequently leads clinicians to prescribe antibiotics to the children with lower respiratory symptoms and signs. Our data show
ed that the oseltamivir-treated children were more likely to have
been tested with IRDT compared to the children treated with
antibiotics or supportive-care. Although all of our study subjects were ultimately proven to have laboratory-confirmed influenza, children who were treated with antibiotics or only supportive-care may have been initially suspected of having bacterial infection or non-viral respiratory illness. Such children were
less likely to undergo testing by IRDT than those oseltamivirtreated, who were more likely to be confirmed with influenza
on admission with IRDT. Our results as well as previous studies
support the notion that IRDT are an important tool for guiding
influenza treatment decision-making (29, 30). Distinguishing
http://dx.doi.org/10.3346/jkms.2014.29.4.485

influenza from other respiratory diseases in children as well as
identifying influenza with atypical clinical presentations is a
well-recognized clinical challenge (31). As a result, increased
accessibility of IRDT is a recognized priority among clinicians
in ROK and elsewhere that is likely to improve patient treatment
regimens and clinical outcomes, as well as potentially reduce
antibiotic usage and additional laboratory testing (29, 30, 32).
In our study, we adjusted for clinical characteristics in our
multivariable analysis that were previously linked to higher influenza viral load, prolonged hospitalization, secondary pneumonia, as well as other viral or bacterial complications (33-38).
We found no consistent treatment-related patterns with respect
to disease severity of illness when compared clinical presentation by treatment type. For example, rales/wheezing were more
commonly present among patients treated with antibiotics-only, antibiotics-plus-oseltamivir, and even supportive-care, compared to those treated with oseltamivir-only, Also, chest infiltrate, which may suggest bacterial pneumonia (39), was not
significantly more common in antibiotics or antibiotics-plusoseltamivir groups compared to the oseltamivir-only group.
There was no currently available and validated severity of illness index for pediatric influenza.
In this retrospective study, our data extraction was limited to
the information available on medical charts. Due to the observational nature of our study, we cannot conclude that oseltamivir shortened the LOS among hospitalized patients with influenza. Although lengthened hospitalization practically directly
reflects the burden of influenza requiring hospitalization, clinical data may not entirely capture the influenza disease burden.
In clinical practice at KU hospitals, the hospitalizations diagnosed with mild conditions (e.g., pharyngitis) were less likely to
be treated with antibiotics, while those with more severe findings, such as rales or chest infiltrate that prompt clinicians to
suspect bacterial pneumonia, were often treated with antibiotics. Thus, variability in illness severity at admission influencing
clinical diagnosis was the most important confounder of this
relationship and various clinical attributes were controlled for
in the analysis.
Despite these limitations, a robust analysis of the treatment
type was possible due to: 1) three complete and consecutive viral seasons; 2) a relatively large sample of laboratory-confirmed
influenza hospitalizations; 3) the geographic and patient mix of
patients from community and academic hospitals in different
parts of ROK, providing a representative sample for greater ge
neralizability of results; and 4) no oseltamivir resistance in the
viral strains during our study period in ROK (anecdotal reports),
minimizing the influence of oseltamivir resistance on the study
outcomes. Prescription patterns could differ by clinician and
facility, but the three hospitals under the umbrella of KU had
highly uniform standards in patient management and treatment
regimen. Moreover, all subjects were culture-confirmed, in adhttp://jkms.org  491
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dition to some that had undergone IRDT, ensuring uniformity
in the levels of sensitivity and specificity of influenza diagnostics. Considering the lack of data from direct comparison between antibiotic and oseltamivir treatments, our study provides
a realistic illustration of influenza treatment in relation to increased hospitalization by comparing treatment options used
in clinical practice in ROK. As suggested by Falagas et al., there
is a need for comparative and randomized studies (40), our study
findings will serve as a platform for further assessment of different influenza treatment options in clinical practice.
In ROK, the predominantly circulating strains were A/H3N2
in 2004-05, A/H1N1 in 2005-06, and A/H3N2 in 2006-07 and
there were no reported oseltamivir-resistant strains of influenza
during the study period of 2004-07. Notably, in the January 2011
issue of the U.S. Centers for Disease Control and Prevention’s
Morbidity and Mortality Weekly Report, either oseltamivir or
zanamivir was recommended for use in patients hospitalized
with suspected or confirmed influenza, whether it is 2009 H1N1
virus, influenza A (H3N2) virus, or influenza B virus or when
the influenza virus type or influenza A virus subtype is unknown
(41). In ROK, there is limited number of oseltamivir treatment
guidelines or recommendations for seasonal influenza. Also,
IRDT is not routinely used in decision-makings of patient management, despite its well-known benefits (23, 32, 37). Lately,
real time RT-PCR is used more often in many facilities in ROK,
which means influenza infection could be detected in earlier
stage of illness with better accuracy.
Recognizing that laboratory-confirmation of influenza at an
earlier point of the course of hospitalization may be particularly
important in pediatric influenza treatment (29, 42), our study
suggests the need for appropriate use of IRDT and RT-PCR for
seasonal influenza in ROK so that more vigilant and judicious
antibiotics prescription could be practiced in the clinical setting.
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